Safety and Efficacy of Exenatide in Patients with Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin

Exclusion Criteria

• - Have participated in this study previously or any other study using
• exenatide (AC2993/LY2148568) or glucagon-like peptide-1 (GLP-1)
• analogs, or have been previously treated with exenatide or GLP-1
• analogs
• - Have participated in an interventional medical, surgical, or pharmaceutical study (a study in which an experimental, drug, medical, or surgical treatment was given) within 30 days of screening. This criterion includes drugs that have not received regulatory approval for any indication at the time of study entry.
• - Have been treated with exogenous insulin for more than 1 week within
• the 2 months prior to screening
• - Used drugs for weight loss (e.g., orlistat, rimonabant, sibutramine, or
• similar over-the-counter medications) within 3 months prior to screening.
• - Are currently treated with any of the following excluded medications:
• • Sulfonylurea or meglitinide derivatives (e.g., repaglinide or nateglinide) within 3 months prior to screening
• • Alpha-glucosidase inhibitor (e.g., miglitol or acarbose) within
• 3 months of screening
• • Dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., sitagliptin or vildagliptin) within 3 months prior to screening
• • Pramlintide acetate injection within 3 months prior to screening
• • Drugs that directly affect gastrointestinal motility, including, but
• not limited to: Metoclopramide, cisapride, and chronic macrolide
• antibiotics
• • Are receiving chronic (lasting longer than 2 weeks) systemic
• glucocorticoid therapy (excluding topical and inhaled preparations)
• or have received such therapy within the 4 weeks immediately
• preceding study start